Together, these findings provide a rationale for exploring combinations of MYC inhibitors with DNA-PKcsi as a strategy to simultaneously suppress oncogenic signalling and the compensatory DNA repair pathways that support cancer cell survival. The gene discussed is MYC; the disease is cancer.